NCT02192515View on ClinicalTrials.gov

A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

January 31, 2016

Conditions
Healthy Subjects
Interventions
DRUG

APD356 10 mg

One tablet of APD356 10 mg will be orally administered in fasted state.

DRUG

APD356 XR-20 mg

One tablet of APD356 XR-20 mg will be orally administered in fasted state.

DRUG

APD356 10 mg matching Placebo

One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.

DRUG

APD356 XR-20 mg matching Placebo

One tablet of APD356 XR matching placebo will be orally administered in fasted state.

DRUG

APD356 20 mg

Two tablets of APD356 10 mg will be orally administered in fasted state.

DRUG

APD356 20 mg matching Placebo

Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.

DRUG

APD356 XR-20 mg (orange tablet)

One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.

DRUG

APD356 XR-20mg (orange tablet, fed state)

One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.

Trial Locations (1)

Unknown

Toshima-Ku

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT02192515 - A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects | Biotech Hunter | Biotech Hunter